Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma

Abstract

This retrospective study was conducted to evaluate the prognostic significance of the preoperative plasma D-dimer levels and platelet counts in patients with pancreatic adenocarcinoma. A total of 168 consecutive locally advanced pancreatic adenocarcinoma patients who underwent intensity modulated radiation therapy with or without chemotherapy were enrolled in this study. Plasma D-dimer levels were measured by a latex-enhanced immunoturbidimetric assay. Of the 168 patients enrolled, 106 patients were males and 62 patients were females. There was significant difference between plasma D-dimer levels and clinical responses (P=0.001). The 1-year, 2-year, and 3-year cumulative overall survival rates were 50.6%, 15.0%, and 4.9%, respectively. Plasma D-dimer levels (P<0.001) and platelet counts (P=0.010) were significantly related with overall survival in univariate analysis. The Cox proportional hazards regression indicated that plasma D-dimer levels (P=0.028), platelet counts (P=0.004), and treatment response (P<0.001) were independent prognostic factors for overall survival. Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma.

Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: a Systematic Review and Meta-Analysis

“…D-dimer concentration was measure by either immunoturbidimetric assay (ITM) or Latex Test with various cut-off values among those studies. Of all eligible studies, Fifteen studies reported on lung cancer [2, 3, 19-31], followed by colorectal cancer (n = 9) [9, 21, 32-38], gastric cancer (n = 5) [21, 39-42], pancreatic cancer (n = 5) [21, 43-46], ovarian cancer (n = 3) [47-49], esophageal cancer (n = 3) [50-52], cervical cancer (n = 2) [6, 7], renal cancer (n = 2) [21, 53], sarcoma cancer (n = 2) [54, 55], brain cancer (n = 2) [21, 56], endometrial cancer (n = 2) [57, 58], breast cancer (n = 1) [21], nasopharyngeal cancer (n = 1) [59], prostate cancer (n = 1) [21], malignant melanoma (n = 1) [60], cholangiocarcinoma (n = 1) [61] and hepatobiliary cancer (n = 1) [62]. Thirteen studies only chose non-metastatic cancer patients as research subjects while six studies only enrolled cancer metastatic patients.…”

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin

“…Examples of prognostic factors for PDA are the tumor marker CA19.9, which is proportional to the tumor burden [25], ALP, which is both an inflammatory and cholestasis marker [26], and d-dimer, which is associated with an enhanced coagulative cascade [27].…”

“…There was no imbalance in KPS between GEM and GEMOXA group (KPS 80 or 90 in 53% and 42% of patients, respectively, chi-square p value = 0.209). Median BMI at treatment start was 23 (range [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34].…”

Fibrinogen and D‐dimer levels elevate in advanced hepatocellular carcinoma: High pretreatment fibrinogen levels predict poor outcomes

“…Previous studies have reported that plasma fibrinogen and/or D‐dimer levels can predict poor prognosis in several types of malignancies including ovarian, breast, colorectal, lung, gastric, and pancreatic cancer . In lung cancer, plasma fibrinogen and D‐dimer levels have been shown to be associated with tumor pathological stage, response to therapy, and survival .…”

“…15,16 Previous studies have reported that plasma fibrinogen and/or D-dimer levels can predict poor prognosis in several types of malignancies including ovarian, 13 breast, 17 colorectal, 18 lung, 19,20 gastric, 21 and pancreatic cancer. 22 In lung cancer, plasma fibrinogen and D-dimer levels have been shown to be associated with tumor pathological stage, response to therapy, and survival. 12,23,24 In epithelial cell origin ovarian cancer, pretreatment plasma D-dimer and fibrinogen have been shown to be able to predict disease progression and surgical outcome as well as to help identify and treat high-risk populations.…”